BioCentury
ARTICLE | Clinical News

Dalazatide: Phase Ib data

May 18, 2015 7:00 AM UTC

Top-line data from the double-blind, Canadian Phase Ib 186-03 trial in 24 patients with active plaque psoriasis showed that twice-weekly 30 and 60 ug doses of subcutaneous dalazatide for 4 weeks were ...